January 22, 2026

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients...

The ASCO Post

January 21, 2026

IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer

Circulating tumor DNA (ctDNA) status after radical cystectomy may be able to guide adjuvant treatment decisions for patients with muscle-invasive bladder cancer, according to phase III data.

The ASCO Post

January 19, 2026

Look Again! Demodex Blepharitis in Closer Focus

Why Demodex blepharitis deserves more attention – and how a quick diagnostic check can improve patient care

The Ophthalmologist

January 14, 2026

Asymptomatic Meibomian Gland Characteristics 

Silent gland failure: what do asymptomatic adults reveal about subclinical MGD?

The Ophthalmologist

January 14, 2026

Empowering Research Leadership: Development of an Intensive Course to Support Oncology Advanced Practitioner Participation in Clinical Trials

A landmark program is empowering oncology advanced practitioners to lead clinical trials, addressing the rising demand in cancer care.

JADPRO

January 13, 2026

Intense Pulsed Light for Dry Eye

Three-session IPL strategy demonstrates stronger, longer-lasting gains for dry eye patients

The Ophthalmologist

January 12, 2026

What Causes Metastasis in Deadly Eye Cancer?

Gene expression profiling sheds new light on malignant transformation in uveal melanoma

The Pathologist

January 12, 2026

Medable Debuts AI Agent for Automating Trial Master File Processes

New capability frees up human capital from one of the biggest labor costs in clinical research

The Medicine Maker

January 09, 2026

Can a Benign Hematology Phenomenon Critically Impact the Neutropenia Status and Treatment of Patients With Cancer?

Understanding benign ethnic neutropenia (BEN) and its implications can prevent unnecessary treatment interruptions for cancer patients of African descent.

JADPRO